cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Enanta Pharmaceuticals Inc
1 own
5 watching
Current Price
$54.59
$1.65
(3.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,134.98M
52-Week High
52-Week High
79.495
52-Week Low
52-Week Low
37.59
Average Volume
Average Volume
0.12M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
363.2224
iconMarket Capitalization1,134.98M
icon52-Week High79.495
icon52-Week Low37.59
iconAverage Volume0.12M
iconDividend Yield--
iconP/E Ratio363.2224
What does the Enanta Pharmaceuticals Inc do?
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Read More
How much money does Enanta Pharmaceuticals Inc make?
News & Events about Enanta Pharmaceuticals Inc.
Ticker Report
8days ago
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA Get Rating) have received an average rating of Moderate Buy from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and ...
Business Wire
1month ago
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., Enantas President and Chief Executive Officer, will provide an update across its pipeline of virology programs...
Ticker Report
2 months ago
Enanta Pharmaceuticals (NASDAQ:ENTA Get Rating)s stock had its buy rating reaffirmed by equities research analysts at JMP Securities in a research report issued on Tuesday, Stock Target Advisor reports. They presently have a $96.00 price objective on the biotechnology ...
Business Wire
5 months ago
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the...
Zolmax
6 months ago
Enanta Pharmaceuticals (NASDAQ:ENTA Get Rating) had its price objective hoisted by JMP Securities from $103.00 to $137.00 in a research report report published on Tuesday , The Fly reports. They currently have a market outperform rating on the biotechnology companys stock. Other equities research ...
Frequently Asked Questions
Frequently Asked Questions
What is Enanta Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Enanta Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Enanta Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Enanta Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Enanta Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Enanta Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Enanta Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Enanta Pharmaceuticals Inc?
plus_minus_icon
What percentage is Enanta Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Enanta Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$54.59
$1.65
(3.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Coherus BioSciences Inc
Coherus BioSciences Inc
$8.42
$0.02 (0.24 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$16.05
$0.06 (0.38 %)
Nevro Corp
Nevro Corp
$38.58
$-0.10 (-0.26 %)
Catalent, Inc.
Catalent, Inc.
$71.58
$4.58 (6.84 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Coherus BioSciences Inc
Coherus BioSciences Inc
$8.42
$0.02 (0.24 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$16.05
$0.06 (0.38 %)
Nevro Corp
Nevro Corp
$38.58
$-0.10 (-0.26 %)
Catalent, Inc.
Catalent, Inc.
$71.58
$4.58 (6.84 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00